Alternative interferons and immunomodulators in the treatment of hepatitis C

Hawwa Alao; T. Jake Liang

doi:10.1111/liv.12402

Alternative interferons and immunomodulators in the treatment of hepatitis C

Hawwa Alao, T. Jake Liang

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Interferon-α (IFN-α) has been the mainstay of therapy for hepatitis C and is currently being combined with other drugs to improve the response rate. Newer therapeutic regimens are being developed to spare the use of IFN because of the important side effects associated with IFN-based therapy. However, there may still be a need for the use of IFN in certain populations. In addition, agents that mimic the actions of IFN but with fewer side effects may still be of major value. This review focuses on the development of alternative and new forms of IFNs and other immunomodulatory agents that may supplant IFN-α in combination therapy for hepatitis C.

Original language	English (US)
Pages (from-to)	133-138
Number of pages	6
Journal	Liver International
Volume	34
Issue number	SUPPL1
DOIs	https://doi.org/10.1111/liv.12402
State	Published - Feb 2014
Externally published	Yes

Keywords

Antiviral drug development
Innate immunity
Interferon enhancer
Toll-like receptors

ASJC Scopus subject areas

Hepatology

Access to Document

10.1111/liv.12402

Cite this

@article{b5011e57e09d4c298250fb4e5feca967,

title = "Alternative interferons and immunomodulators in the treatment of hepatitis C",

abstract = "Interferon-α (IFN-α) has been the mainstay of therapy for hepatitis C and is currently being combined with other drugs to improve the response rate. Newer therapeutic regimens are being developed to spare the use of IFN because of the important side effects associated with IFN-based therapy. However, there may still be a need for the use of IFN in certain populations. In addition, agents that mimic the actions of IFN but with fewer side effects may still be of major value. This review focuses on the development of alternative and new forms of IFNs and other immunomodulatory agents that may supplant IFN-α in combination therapy for hepatitis C.",

keywords = "Antiviral drug development, Innate immunity, Interferon enhancer, Toll-like receptors",

author = "Hawwa Alao and {Jake Liang}, T.",

year = "2014",

month = feb,

doi = "10.1111/liv.12402",

language = "English (US)",

volume = "34",

pages = "133--138",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell",

number = "SUPPL1",

}

TY - JOUR

T1 - Alternative interferons and immunomodulators in the treatment of hepatitis C

AU - Alao, Hawwa

AU - Jake Liang, T.

PY - 2014/2

Y1 - 2014/2

N2 - Interferon-α (IFN-α) has been the mainstay of therapy for hepatitis C and is currently being combined with other drugs to improve the response rate. Newer therapeutic regimens are being developed to spare the use of IFN because of the important side effects associated with IFN-based therapy. However, there may still be a need for the use of IFN in certain populations. In addition, agents that mimic the actions of IFN but with fewer side effects may still be of major value. This review focuses on the development of alternative and new forms of IFNs and other immunomodulatory agents that may supplant IFN-α in combination therapy for hepatitis C.

AB - Interferon-α (IFN-α) has been the mainstay of therapy for hepatitis C and is currently being combined with other drugs to improve the response rate. Newer therapeutic regimens are being developed to spare the use of IFN because of the important side effects associated with IFN-based therapy. However, there may still be a need for the use of IFN in certain populations. In addition, agents that mimic the actions of IFN but with fewer side effects may still be of major value. This review focuses on the development of alternative and new forms of IFNs and other immunomodulatory agents that may supplant IFN-α in combination therapy for hepatitis C.

KW - Antiviral drug development

KW - Innate immunity

KW - Interferon enhancer

KW - Toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=84890891316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890891316&partnerID=8YFLogxK

U2 - 10.1111/liv.12402

DO - 10.1111/liv.12402

M3 - Article

C2 - 24373090

AN - SCOPUS:84890891316

SN - 1478-3223

VL - 34

SP - 133

EP - 138

JO - Liver International

JF - Liver International

IS - SUPPL1

ER -

Alternative interferons and immunomodulators in the treatment of hepatitis C

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this